The dark matter of diffuse intrinsic pontine gliomas: an update

References

• Wu G, Broniscer A, McEachron TA, et al. St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet. 2012;44(3):251–253.
   PubMed Web of Science ®Google Scholar
• Geoerger B, Morland B, Ndiaye A, et al. Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium. Eur J Cancer. 2009 Sep;45(13):2342–2351.
   PubMed Web of Science ®Google Scholar
• Puget S, Beccaria K, Blauwblomme T, et al. Biopsy in a series of 130 pediatric diffuse intrinsic pontine gliomas. Childs Nerv Syst. 2015 Oct;31(10):1773–1780.
   PubMed Web of Science ®Google Scholar
• Gupta N, Goumnerova LJ, Manley P, et al. Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. Neuro Oncol. 2018 Oct 9;20(11):1547–1555.
   PubMed Web of Science ®Google Scholar
• Guillain G, Bertrand I, Gruner J. Les Gliomes Infiltres du Tronc Cerebral. Paris: Masson Editor; 1945.
   Google Scholar
• Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012 Jan 29;482(7384):226–231.
   PubMed Web of Science ®Google Scholar
• Coutel Y. Infiltrating glioblastoma of the brain stem in an 8-year-old child; normalization of the pneumoencephalogram after radiotherapy. Rev Otoneuroophtalmol. 1959;31:119–123.
   PubMedGoogle Scholar
• Jansen MH, Veldhuijzen van Zanten SE, Sanchez Aliaga E, et al. Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria. Neuro Oncol. 2015 Jan;17(1):160–166.
   PubMed Web of Science ®Google Scholar
• Lewis PW, Müller MM, Koletsky MS, et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science. 2013 May 17;340(6134):857–861.
   PubMed Web of Science ®Google Scholar
• Bender S, Tang Y, Lindroth AM, et al. Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell. 2013 Nov 11;24(5):660–672.
   PubMed Web of Science ®Google Scholar
• Castel D, Philippe C, Calmon R, et al. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol. 2015 Dec;130(6):815–827.
   PubMed Web of Science ®Google Scholar
• Filipescu D, Müller S, Almouzni G. Histone H3 variants and their chaperones during development and disease: contributing to epigenetic control. Annu Rev Cell Dev Biol. 2014;30:615–646.
   PubMed Web of Science ®Google Scholar
• Tatavosian R, Duc HN, Huynh TN, et al. Live-cell single-molecule dynamics of PcG proteins imposed by the DIPG H3.3K27M mutation. Nat Commun. 2018 May 25;9(1):2080.
   PubMedGoogle Scholar
• Mohammad F, Weissmann S, Leblanc B, et al. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Nat Med. 2017 Apr;23(4):483–492.
   PubMed Web of Science ®Google Scholar
• Fang D, Gan H, Cheng L, et al. H3.3K27M mutant proteins reprogram epigenome by sequestering the PRC2 complex to poised enhancers. eLife. 2018;7:e36696.
   PubMed Web of Science ®Google Scholar
• Pajtler KW, Wen J, Sill M, et al. Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. Acta Neuropathol. 2018 Jun 16. Epub ahead of print. DOI:10.1007/s00401-018-1877-0.
   Web of Science ®Google Scholar
• Taylor KR, Mackay A, Truffaux N. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet. 2014 May;46(5):457–461.
   PubMed Web of Science ®Google Scholar
• Grill J, Puget S, Andreiuolo F, et al. Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma. Pediatr Blood Cancer. 2012 Apr;58(4):489–491.
   PubMed Web of Science ®Google Scholar
• Mackay A, Burford A, Carvalho D, et al. Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell. 2017 Oct 9;32(4):520–537.e5.
   PubMed Web of Science ®Google Scholar
• Puget S, Philippe C, Bax DA, et al. Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas. PLoS One. 2012;7(2):e30313.
   PubMed Web of Science ®Google Scholar
• Paugh BS, Zhu X, Qu C, et al. Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas. Cancer Res. 2013 Oct 15;73(20):6219–6229.
   PubMed Web of Science ®Google Scholar
• Truffaux N, Philippe C, Paulsson J, et al. Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma. Neuro Oncol. 2015 Jul;17(7):953–964.
   PubMed Web of Science ®Google Scholar
• Nikbakht H, Panditharatna E, Mikael LG, et al. Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nat Commun. 2016 Apr;6(7):11185.
   Google Scholar
• Hoffman LM, DeWire M, Ryall S, et al. Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics. Acta Neuropathol Commun. 2016 Jan;4(4):1.
   PubMedGoogle Scholar
• Nazarian J, Mason GE, Ho CY, et al. Histological and molecular analysis of a progressive diffuse intrinsic pontine glioma and synchronous metastatic lesions: a case report. Oncotarget. 2016 Jul 5;7(27):42837–42842.
   PubMedGoogle Scholar
• Buczkowicz P, Hoeman C, Rakopoulos P. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet. 2014 May;46(5):451–456.
   PubMed Web of Science ®Google Scholar
• Vinci M, Burford A, Molinari V. Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells. Nat Med. 2018 Aug;24(8):1204–1215.
   PubMed Web of Science ®Google Scholar
• Fontebasso AM, Papillon-Cavanagh S, Schwartzentruber J, et al. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat Genet. 2014 May;46(5):462–466.
   PubMed Web of Science ®Google Scholar
• Wu G, Diaz AK, Paugh BS, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet. 2014 May;46(5):444–450.
   PubMed Web of Science ®Google Scholar
• Zarghooni M, Bartels U, Lee E, et al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol. 2010 Mar 10;28(8):1337–1344.
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016 Jun;131(6):803–820.
   PubMed Web of Science ®Google Scholar
• Karremann M, Gielen GH, Hoffmann M, et al. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. Neuro Oncol. 2018 Jan 10;20(1):123–131.
   PubMed Web of Science ®Google Scholar
• Mackay A, Burford A, Molinari V, et al. Molecular, pathological, radiological, and immune profiling of non-brainstem pediatric high-grade glioma from the HERBY phase II randomized trial. Cancer Cell. 2018 May 14;33(5):829–842.e5.
   PubMed Web of Science ®Google Scholar
• Buczkowicz P, Bartels U, Bouffet E, et al. Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. Acta Neuropathol. 2014 Oct;128(4):573–581.
   PubMed Web of Science ®Google Scholar
• Janssens GO, Gandola L, Bolle S, et al. Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group. Eur J Cancer. 2017 Mar;73:38–47.
   PubMed Web of Science ®Google Scholar
• Lobon-Iglesias MJ, Giraud G, Castel D, et al. Diffuse intrinsic pontine gliomas (DIPG) at recurrence: is there a window to test new therapies in some patients? J Neurooncol. 2018 Mar;137(1):111–118.
   PubMed Web of Science ®Google Scholar
• Hoffman LM, Veldhuijzen van Zanten SEM, Colditz N, et al. Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A collaborative report from the International and European Society for Pediatric Oncology DIPG Registries. J Clin Oncol. 2018 Jul 1;36(19):1963–1972.
   PubMed Web of Science ®Google Scholar
• Hochart A, Escande F, Rocourt N, et al. Long survival in a child with a mutated K27M-H3.3 pilocytic astrocytoma. Ann Clin Transl Neurol. 2015 Apr;2(4):439–443.
   PubMed Web of Science ®Google Scholar
• Joyon N, Tauziède-Espariat A, Alentorn A, et al. K27M mutation in H3F3A in ganglioglioma grade I with spontaneous malignant transformation extends the histopathological spectrum of the histone H3 oncogenic pathway. Neuropathol Appl Neurobiol. 2017 Apr;43(3):271–276.
   PubMed Web of Science ®Google Scholar
• Becher OJ, Hambardzumyan D, Walker TR, et al. Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma. Cancer Res. 2010 Mar 15;70(6):2548–2557.
   PubMed Web of Science ®Google Scholar
• Funato K, Major T, Lewis PW, et al. Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation. Science. 2014 Dec 19;346(6216):1529–1533.
   PubMed Web of Science ®Google Scholar
• Pathania M, De Jay N, Maestro N, et al. H3.3K27M cooperates with Trp53 loss and PDGFRA gain in mouse embryonic neural progenitor cells to induce invasive high-grade gliomas. Cancer Cell. 2017 Nov 13;32(5):684–700.e9.
   PubMed Web of Science ®Google Scholar
• Reyes-Botero G, Giry M, Mokhtari K, et al. Molecular analysis of diffuse intrinsic brainstem gliomas in adults. J Neurooncol. 2014 Jan;116(2):405–411.
   PubMed Web of Science ®Google Scholar
• Lindquist RA, Guinto CD, Rodas-Rodriguez JL, et al. Identification of proliferative progenitors associated with prominent postnatal growth of the pons. Nat Commun. 2016 May;18(7):11628.
   Google Scholar
• Filbin MG, Tirosh I, Hovestadt V, et al. Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science. 2018 Apr 20;360(6386):331–335.
   PubMed Web of Science ®Google Scholar
• Monje M, Mitra SS, Freret ME, et al. Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proc Natl Acad Sci USA. 2011 Mar 15;108(11):4453–4458.
   PubMed Web of Science ®Google Scholar
• Lin GL, Nagaraja S, Filbin MG, et al. Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma. Acta Neuropathol Commun. 2018 Jun 28;6(1):51.
   PubMedGoogle Scholar
• Goya-Outi J, Orlhac F, Calmon R, et al. Computation of reliable textural indices from multimodal brain MRI: suggestions based on a study of patients with diffuse intrinsic pontine glioma. Phys Med Biol. 2018 May 10;63(10):105003.
   PubMed Web of Science ®Google Scholar
• Hashizume R, Andor N, Ihara Y, et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat Med. 2014 Dec;20(12):1394–1396.
   PubMed Web of Science ®Google Scholar
• Grasso CS, Tang Y, Truffaux N, et al. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat Med. 2015 Jun;21(6):555–559.
   PubMed Web of Science ®Google Scholar
• Piunti A, Hashizume R, Morgan MA, et al. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nat Med. 2017 Apr;23(4):493–500.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Dong W, Zhu J, et al. Combination of EZH2 inhibitor and BET inhibitor for treatment of diffuse intrinsic pontine glioma. Cell Biosci. 2017 Oct 30;7:56.
   PubMed Web of Science ®Google Scholar
• Wiese M, Schill F, Sturm D, et al. No significant cytotoxic effect of the EZH2 inhibitor tazemetostat (EPZ-6438) on pediatric glioma cells with wildtype histone 3 or mutated histone 3.3. Klin Padiatr. 2016 Apr;228(3):113–117.
   PubMed Web of Science ®Google Scholar
• Nagaraja S, Vitanza NA, Woo PJ, et al. Transcriptional dependencies in diffuse intrinsic pontine glioma. Cancer Cell. 2017 May 8;31(5):635–652.e6.
   PubMed Web of Science ®Google Scholar
• Brown ZZ, Müller MM, Jain SU, et al. Strategy for “detoxification” of a cancer-derived histone mutant based on mapping its interaction with the methyltransferase PRC2. J Am Chem Soc. 2014 Oct 1;136(39):13498–13501.
   PubMed Web of Science ®Google Scholar
• Buczkowicz P, Zarghooni M, Bartels U, et al. Aurora kinase B is a potential therapeutic target in pediatric diffuse intrinsic pontine glioma. Brain Pathol. 2013 May;23(3):244–253.
   PubMed Web of Science ®Google Scholar
• Tsoli M, Liu J, Franshaw L, et al. Dual targeting of mitochondrial function and mTOR pathway as a therapeutic strategy for diffuse intrinsic pontine glioma. Oncotarget. 2018 Jan 8;9(7):7541–7556.
   PubMedGoogle Scholar
• Veringa SJ, Biesmans D, van Vuurden DG, et al. In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma. PLoS One. 2013 Apr 29;8(4):e61512.
   PubMed Web of Science ®Google Scholar
• Mittapalli RK, Chung AH, Parrish KE, et al. ABCG2 and ABCB1 limit the efficacy of dasatinib in a PDGF-B-driven brainstem glioma model. Mol Cancer Ther. 2016 May;15(5):819–829.
   PubMed Web of Science ®Google Scholar
• Jansen MH, Lagerweij T, Sewing AC, et al. Bevacizumab targeting diffuse intrinsic pontine glioma: results of 89Zr-Bevacizumab PET imaging in brain tumor models. Mol Cancer Ther. 2016 Sep;15(9):2166–2174.
   PubMed Web of Science ®Google Scholar
• Veldhuijzen van Zanten SEM, Sewing ACP, van Lingen A, et al. Multiregional tumor drug-uptake imaging by PET and microvascular morphology in end-stage diffuse intrinsic pontine glioma. J Nucl Med. 2018 Apr;59(4):612–615.
   PubMed Web of Science ®Google Scholar
• Lewis O, Woolley M, Johnson D, et al. Chronic, intermittent convection-enhanced delivery devices. J Neurosci Methods. 2016 Feb;1(259):47–56.
   Google Scholar
• Souweidane MM, Kramer K, Pandit-Taskar N, et al. Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial. Lancet Oncol. 2018 Aug;19(8):e382.
   PubMed Web of Science ®Google Scholar
• Carpentier A, Canney M, Vignot A, et al. Clinical trial of blood-brain barrier disruption by pulsed ultrasound. Sci Transl Med. 2016 Jun 15;8(343):343re2.
   PubMed Web of Science ®Google Scholar